NI201800031A - Derivados de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa - Google Patents
Derivados de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopaInfo
- Publication number
- NI201800031A NI201800031A NI201800031A NI201800031A NI201800031A NI 201800031 A NI201800031 A NI 201800031A NI 201800031 A NI201800031 A NI 201800031A NI 201800031 A NI201800031 A NI 201800031A NI 201800031 A NI201800031 A NI 201800031A
- Authority
- NI
- Nicaragua
- Prior art keywords
- levodopa
- chromone
- therapy
- oxima
- derivatives
- Prior art date
Links
- 210000004556 brain Anatomy 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 208000012661 Dyskinesia Diseases 0.000 title 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 title 1
- 230000000149 penetrating effect Effects 0.000 title 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 2
- 229960004502 levodopa Drugs 0.000 abstract 2
- IPDGWIYTNQXKSP-UHFFFAOYSA-N n-chromen-4-ylidenehydroxylamine Chemical class C1=CC=C2C(=NO)C=COC2=C1 IPDGWIYTNQXKSP-UHFFFAOYSA-N 0.000 abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000003257 excitatory amino acid Substances 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un derivado de oxima de cromona de la fórmula (I), que es un modulador de los receptores del sistema nervioso sensibles al glutamato de aminoácido neuroexcitatorio y presenta una exposición cerebral convenientemente alta con la administración oral, para el tratamiento o prevención de disquenesia inducida por levodopa. La presente invención también proporciona una terapia mejorada de la enfermedad de Parkinson, utilizando el derivado de oxima de cromona de la fórmula (I) en combinación con levodopa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/069601 WO2016030444A1 (en) | 2014-08-27 | 2015-08-27 | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors |
| EP15188368 | 2015-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201800031A true NI201800031A (es) | 2018-08-30 |
Family
ID=54260666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201800031A NI201800031A (es) | 2015-08-27 | 2018-02-23 | Derivados de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US10532057B2 (es) |
| EP (2) | EP3341380B1 (es) |
| JP (1) | JP2018528205A (es) |
| KR (1) | KR20180041234A (es) |
| CN (1) | CN108349993A (es) |
| AU (1) | AU2016313138A1 (es) |
| CA (1) | CA2995313A1 (es) |
| CL (1) | CL2018000497A1 (es) |
| CY (1) | CY1122401T1 (es) |
| DK (1) | DK3341380T3 (es) |
| DO (1) | DOP2018000060A (es) |
| EA (1) | EA035016B1 (es) |
| ES (1) | ES2764490T3 (es) |
| HR (1) | HRP20192250T1 (es) |
| HU (1) | HUE047531T2 (es) |
| IL (1) | IL257655A (es) |
| LT (1) | LT3341380T (es) |
| MA (1) | MA42700B1 (es) |
| ME (1) | ME03591B (es) |
| MX (1) | MX2018002255A (es) |
| NI (1) | NI201800031A (es) |
| PH (1) | PH12018500430A1 (es) |
| PL (1) | PL3341380T3 (es) |
| PT (1) | PT3341380T (es) |
| RS (1) | RS59651B1 (es) |
| RU (1) | RU2018110580A (es) |
| SI (1) | SI3341380T1 (es) |
| TN (1) | TN2018000061A1 (es) |
| WO (1) | WO2017032874A1 (es) |
| ZA (1) | ZA201801642B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03339B (me) * | 2014-08-27 | 2019-10-20 | Prexton Therapeutics Sa | Novi derivat hromon oksima i njegova upotreba kao alosterni modulator metabotropnih glutamatnih receptora |
| ES2764490T3 (es) | 2015-08-27 | 2020-06-03 | Prexton Therapeutics Sa | Derivado de oxima de cromona que penetra en el cerebro para la terapia de la discinesia inducida por levodopa |
| EP3827001A1 (en) | 2018-07-26 | 2021-06-02 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 |
| CN112533750A (zh) | 2018-12-14 | 2021-03-19 | 惠普发展公司，有限责任合伙企业 | 评估候选虚拟构建卷 |
| CN115594655B (zh) * | 2022-09-16 | 2023-08-15 | 桂林医学院 | 色酮肟类衍生物及其制备方法和应用 |
| KR20240080457A (ko) * | 2022-11-30 | 2024-06-07 | 주식회사한국파마 | 신경퇴행성 질환 예방 또는 치료용 필름코팅정제 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4065467A (en) | 1973-12-27 | 1977-12-27 | Carlo Erba, S. P. A. | 5:6-Benzo δ-pyrone derivatives and process for their preparation |
| US4777252A (en) | 1987-08-13 | 1988-10-11 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines |
| US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
| JP3993651B2 (ja) | 1994-10-21 | 2007-10-17 | アスビオファーマ株式会社 | シクロプロパクロメンカルボン酸誘導体 |
| EP1298129A3 (en) | 2001-09-28 | 2003-06-04 | Central Glass Company, Limited | Process for producing 4-sustituted benzopyran derivatives |
| PE20040801A1 (es) | 2002-12-12 | 2004-11-25 | Hoffmann La Roche | Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa |
| EP1615906A1 (en) | 2003-04-03 | 2006-01-18 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| WO2007011701A1 (en) | 2005-07-15 | 2007-01-25 | Transform Pharmaceuticals, Inc. | Novel hydrochloride salts of levodopa |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| EA201070143A1 (ru) | 2007-07-13 | 2010-08-30 | Аддекс Фарма С.А. | Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов |
| JP5806672B2 (ja) * | 2009-10-30 | 2015-11-10 | ドメイン・セラピューティクス | 新規オキシム誘導体及び代謝型グルタミン酸受容体のアロステリック調節因子としての利用 |
| NZ600008A (en) | 2009-12-04 | 2014-10-31 | Sunovion Pharmaceuticals Inc | Multicyclic compounds and methods of use thereof |
| WO2011107653A2 (en) * | 2010-03-04 | 2011-09-09 | Orion Corporation | Method for treating parkinson's disease |
| ME03339B (me) * | 2014-08-27 | 2019-10-20 | Prexton Therapeutics Sa | Novi derivat hromon oksima i njegova upotreba kao alosterni modulator metabotropnih glutamatnih receptora |
| ES2764490T3 (es) | 2015-08-27 | 2020-06-03 | Prexton Therapeutics Sa | Derivado de oxima de cromona que penetra en el cerebro para la terapia de la discinesia inducida por levodopa |
-
2016
- 2016-08-26 ES ES16769872T patent/ES2764490T3/es active Active
- 2016-08-26 PL PL16769872T patent/PL3341380T3/pl unknown
- 2016-08-26 DK DK16769872.9T patent/DK3341380T3/da active
- 2016-08-26 JP JP2018510876A patent/JP2018528205A/ja active Pending
- 2016-08-26 RS RS20191571A patent/RS59651B1/sr unknown
- 2016-08-26 CA CA2995313A patent/CA2995313A1/en not_active Abandoned
- 2016-08-26 ME MEP-2019-346A patent/ME03591B/me unknown
- 2016-08-26 CN CN201680062784.8A patent/CN108349993A/zh active Pending
- 2016-08-26 MX MX2018002255A patent/MX2018002255A/es unknown
- 2016-08-26 EA EA201890590A patent/EA035016B1/ru not_active IP Right Cessation
- 2016-08-26 TN TNP/2018/000061A patent/TN2018000061A1/en unknown
- 2016-08-26 EP EP16769872.9A patent/EP3341380B1/en active Active
- 2016-08-26 WO PCT/EP2016/070175 patent/WO2017032874A1/en active Application Filing
- 2016-08-26 EP EP19207959.8A patent/EP3696182A1/en not_active Withdrawn
- 2016-08-26 PT PT167698729T patent/PT3341380T/pt unknown
- 2016-08-26 RU RU2018110580A patent/RU2018110580A/ru not_active Application Discontinuation
- 2016-08-26 MA MA42700A patent/MA42700B1/fr unknown
- 2016-08-26 HU HUE16769872A patent/HUE047531T2/hu unknown
- 2016-08-26 SI SI201630559T patent/SI3341380T1/sl unknown
- 2016-08-26 US US15/755,435 patent/US10532057B2/en not_active Expired - Fee Related
- 2016-08-26 KR KR1020187008542A patent/KR20180041234A/ko unknown
- 2016-08-26 LT LTEP16769872.9T patent/LT3341380T/lt unknown
- 2016-08-26 AU AU2016313138A patent/AU2016313138A1/en not_active Abandoned
-
2018
- 2018-02-21 IL IL257655A patent/IL257655A/en unknown
- 2018-02-23 CL CL2018000497A patent/CL2018000497A1/es unknown
- 2018-02-23 NI NI201800031A patent/NI201800031A/es unknown
- 2018-02-26 DO DO2018000060A patent/DOP2018000060A/es unknown
- 2018-02-27 PH PH12018500430A patent/PH12018500430A1/en unknown
- 2018-03-09 ZA ZA2018/01642A patent/ZA201801642B/en unknown
-
2019
- 2019-12-10 CY CY20191101297T patent/CY1122401T1/el unknown
- 2019-12-11 US US16/709,988 patent/US20200171042A1/en not_active Abandoned
- 2019-12-13 HR HRP20192250TT patent/HRP20192250T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201800031A (es) | Derivados de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa | |
| ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| CL2015002641A1 (es) | Método para el tratamiento de la enfermedad de parkinson. | |
| BR112017005104A2 (pt) | derivado de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina | |
| CL2019001685A1 (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares. | |
| CR20120255A (es) | Derivados de purina o deazapurina útiles para el tratamiento de inter alia infecciones virales | |
| PE20151771A1 (es) | Composiciones nutricionales que contienen un componente neurologico y los usos del mismo | |
| CL2020000383A1 (es) | Composiciones de aminoácidos para el tratamiento de lesión neuronal. | |
| CL2017000782A1 (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
| CR20190468A (es) | Métodos para tratar enfermedades y trastornos mediados por completo | |
| CL2018002692A1 (es) | Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961) | |
| CL2018001395A1 (es) | Composiciones farmacéuticas que comprenden amida de levodopa y sus uso | |
| CU20200012A7 (es) | Composiciones de aminoácidos para el tratamiento de enfermedad hepática | |
| MX2016011837A (es) | Composiciones de inhibidores de la dopa decarboxilasa. | |
| BR112017010311A2 (pt) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| GT201600250A (es) | Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| BR112019002730A2 (pt) | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa | |
| EA201991374A1 (ru) | Водорастворимое производное эпиаллопрегнанолона и его применение | |
| BR112017000312A2 (pt) | sistema de tratamento da saúde bucal para a aplicação de fosfato de cálcio amorfo, uso de um ou mais aminoácidos básicos, composição, e uso de um ou mais aminoácidos em um sistema de tratamento da saúde bucal | |
| BR112017013674A2 (pt) | métodos e composições para tratamento de doenças cerebrais. | |
| AR105089A1 (es) | ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN | |
| CL2020001495A1 (es) | Composiciones y método para el tratamiento de enfermedades metabólicas | |
| AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
| BR112019000946A2 (pt) | compostos para imagiologia dos agregados da proteína tau | |
| BR112020022088A8 (pt) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina |